Related Experiment Video
Updated: Mar 10, 2026
08:39
Murine Colitis Modeling using Dextran Sulfate Sodium DSS
Published on: January 19, 2010
51.2K
Deoxyschizandrin suppresses dss-induced ulcerative colitis in mice
Wen-Feng Zhang1, Yan Yang1, Xin Su1
1Changchun University of Chinese Medicine, Changchun Jingyue Street, Boshuo Road 1035, Changchun, Jilin, China.
Summary
Deoxyschizandrin, a compound from Schisandra chinensis, effectively reduces inflammation, T cell infiltration, and apoptosis in mouse models of ulcerative colitis. This suggests its potential as a therapeutic agent for treating this condition.
Area of Science:
- Pharmacology
- Immunology
- Gastroenterology
Background:
- Deoxyschizandrin, a key component of Schisandra chinensis, exhibits immunomodulatory properties.
- Its therapeutic potential in ulcerative colitis (UC) requires further investigation.
- Ulcerative colitis is a chronic inflammatory bowel disease with significant unmet medical needs.
Purpose of the Study:
- To investigate the therapeutic effects of deoxyschizandrin in a mouse model of DSS-induced ulcerative colitis.
- To elucidate the mechanisms underlying deoxyschizandrin's action, focusing on inflammation, apoptosis, and immune cell infiltration.
Main Methods:
- An in vitro inflammation model was used to assess deoxyschizandrin's anti-inflammatory effects.
- A mouse model of ulcerative colitis was induced using Dextran Sulfate Sodium (DSS).
- Colon inflammation, apoptosis, and CD4 T lymphocyte infiltration were evaluated using histological and molecular analyses.
Main Results:
- Deoxyschizandrin significantly ameliorated DSS-induced ulcerative colitis symptoms.
- Histopathological examination revealed reduced colon inflammation and improved tissue integrity.
- Deoxyschizandrin suppressed inflammatory cytokine levels, inhibited CD4 T cell infiltration, and reduced apoptosis in the colon.
Conclusions:
- Deoxyschizandrin demonstrates significant therapeutic potential for ulcerative colitis.
- Its efficacy is attributed to the inhibition of colonic inflammation, T cell infiltration, and apoptosis.
- Further research into deoxyschizandrin as a novel treatment for ulcerative colitis is warranted.
